Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
作者： Mitchell L. Shiffman , Rafael Esteban
DOI: 10.1111/J.1478-3231.2011.02718.X
关键词:
摘要: Boceprevir and telaprevir are the first two protease inhibitors available for treatment of patients infected with hepatitis C virus (HCV) genotype 1. A sustained virological response (SVR) 70-80% is observed when either these utilized pegylated interferon (PEG-IFN) ribavirin (RBV) in naive patients. Both agents also highly effective who failed to achieve a SVR during previous PEG-IFN/RBV. rapid (RVR) 56-60% Patients RVR can be treated shorter course therapy (24-28 weeks) still rate 90% or higher. do not RVR, those cirrhosis certain prior non-responders should 48 weeks. Although rates boceprevir quite similar both globally within sub-populations, algorithms unique. The decision which inhibitor use assess several factors including scheme, duration therapy, adverse event profile, cost likelihood achieving RVR. latter dependent upon IFN sensitivity IL28B genotype.
sci-hub.se 参考文章(23)
Mitchell L. Shiffman, HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended? Current Hepatitis Reports. ,vol. 10, pp. 4- 10 ,(2011) , 10.1007/S11901-010-0077-8
Eugene R. Schiff, F. Martin Tagle, TREATMENT OF HCV: Approach to Difficult Cases Clinics in Liver Disease. ,vol. 1, pp. 647- 662 ,(1997) , 10.1016/S1089-3261(05)70327-5
Simone Susser, Johannes Vermehren, Nicole Forestier, Martin Walter Welker, Natalia Grigorian, Caterina Füller, Dany Perner, Stefan Zeuzem, Christoph Sarrazin, Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology. ,vol. 52, pp. 321- 327 ,(2011) , 10.1016/J.JCV.2011.08.015
Michael W. Fried, Mitchell L. Shiffman, K. Rajender Reddy, Coleman Smith, George Marinos, Fernando L. Gonçales, Dieter Häussinger, Moises Diago, Giampiero Carosi, Daniel Dhumeaux, Antonio Craxi, Amy Lin, Joseph Hoffman, Jian Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine. ,vol. 347, pp. 975- 982 ,(2002) , 10.1056/NEJMOA020047
Peter Ferenci, Hermann Laferl, Thomas–Matthias Scherzer, Michael Gschwantler, Andreas Maieron, Harald Brunner, Rudolf Stauber, Martin Bischof, Bernhard Bauer, Christian Datz, Karin Löschenberger, Elisabeth Formann, Katharina Staufer, Petra Steindl–Munda, Austrian Hepatitis Study Group, Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response Gastroenterology. ,vol. 135, pp. 451- 458 ,(2008) , 10.1053/J.GASTRO.2008.04.015
Nezam H Afdhal, John G McHutchison, Stefan Zeuzem, Alessandra Mangia, Jean‐Michel Pawlotsky, Jeffrey S Murray, Kevin V Shianna, Yasuhito Tanaka, David L Thomas, David R Booth, David B Goldstein, Pharmacogenetics and Hepatitis C Meeting Participants, None, Hepatitis C pharmacogenetics: State of the art in 2010†‡§ Hepatology. ,vol. 53, pp. 336- 345 ,(2011) , 10.1002/HEP.24052
Bruce R Bacon, Stuart C Gordon, Eric Lawitz, Patrick Marcellin, John M Vierling, Stefan Zeuzem, Fred Poordad, Zachary D Goodman, Heather L Sings, Navdeep Boparai, Margaret Burroughs, Clifford A Brass, Janice K Albrecht, Rafael Esteban, None, Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection The New England Journal of Medicine. ,vol. 364, pp. 1207- 1217 ,(2011) , 10.1056/NEJMOA1009482
Mitchell L. Shiffman, Treatment of hepatitis C in 2011: what can we expect? Current Gastroenterology Reports. ,vol. 12, pp. 70- 75 ,(2010) , 10.1007/S11894-009-0085-4
Dongliang Ge, Jacques Fellay, Alexander J. Thompson, Jason S. Simon, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen, Ping Qiu, Arthur H. Bertelsen, Andrew J. Muir, Mark Sulkowski, John G. McHutchison, David B. Goldstein, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature. ,vol. 461, pp. 399- 401 ,(2009) , 10.1038/NATURE08309
Donald M. Jensen, Timothy R. Morgan, Patrick Marcellin, Paul J. Pockros, K. Rajender Reddy, Stephanos J. Hadziyannis, Peter Ferenci, Andrew M. Ackrill, Bernard Willems, Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy†‡§ Hepatology. ,vol. 43, pp. 954- 960 ,(2006) , 10.1002/HEP.21159